CD44-targeted therapy of breast cancer might therefore require a continuous administration of the P245 mAb, as is the case for other antibody-based therapies, such as with the anti-HER2 mAb (trastuzumab) (Hudis, 2007). The gene discussed is ERBB2; the disease is breast carcinoma.